“Alzinova is in an incredibly exciting situation where we have received increased interest from the industry for our drug candidate ALZ-101. We are also very much looking forward to receiving data in the fourth quarter of 2024 from the extension part of the phase 1b study as well as data from the high-dose cohort that will be presented in the first quarter of 2025. I am very positive about Alzinova's future, so it was obvious for us to increase our holding in Alzinova”, says Anders Blom, Chairman of the Board of Maida Vale Capital AB and Board member of Alzinova.

Following the transactions, Maida Vale Capital AB own a total of approximately 14.6 million shares in the Company. The transactions have been reported to the Swedish Financial Supervisory Authority in accordance with applicable regulations.

For more information, please contact:
Carol Routledge, Acting CEO
Tel: +44 7909002418
E-post: carol.routledge@alzinova.com

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com